应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
DXCM 德康医疗
已收盘 08-12 16:00:00 EDT
90.80
+1.27
+1.42%
盘后
90.63
-0.17
-0.19%
19:34 EDT
最高
91.04
最低
88.27
成交量
540.25万
今开
89.04
昨收
89.53
日振幅
3.10%
总市值
342.64亿
流通市值
341.41亿
总股本
3.77亿
成交额
4.86亿
换手率
1.44%
流通股本
3.76亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读|德康医疗盘中下跌5.01%,报82.58美元
行情直击 · 08-05
异动解读|德康医疗盘中下跌5.01%,报82.58美元
Canaccord Genuity上调德康医疗目标价至90美元
格隆汇 · 08-04
Canaccord Genuity上调德康医疗目标价至90美元
小摩上调德康医疗目标价至82美元
格隆汇 · 08-03
小摩上调德康医疗目标价至82美元
异动解读|德康医疗盘中上涨7.4%,Q2业绩全面超预期并上调全年营收指引
行情直击 · 07-31
异动解读|德康医疗盘中上涨7.4%,Q2业绩全面超预期并上调全年营收指引
异动解读|德康医疗盘前上涨6.65%,Q2业绩全面超预期并上调全年营收指引
行情直击 · 07-31
异动解读|德康医疗盘前上涨6.65%,Q2业绩全面超预期并上调全年营收指引
异动解读 | 德康医疗夜盘大涨8.18%,Q2业绩全面超预期并上调全年指引
异动解读 · 07-31
异动解读 | 德康医疗夜盘大涨8.18%,Q2业绩全面超预期并上调全年指引
德康医疗Q2业绩超预期,上调全年营收指引的下限
格隆汇 · 07-31
德康医疗Q2业绩超预期,上调全年营收指引的下限
异动解读 | 德康医疗夜盘大涨7.28%,Q2财报超预期并上调全年营收指引
异动解读 · 07-31
异动解读 | 德康医疗夜盘大涨7.28%,Q2财报超预期并上调全年营收指引
异动解读|德康医疗夜盘上涨7.28%,Q2业绩全面超预期并上调全年指引
行情直击 · 07-31
异动解读|德康医疗夜盘上涨7.28%,Q2业绩全面超预期并上调全年指引
异动解读 | 财报超预期并上调全年指引,德康医疗盘后大涨近6%
异动解读 · 07-31
异动解读 | 财报超预期并上调全年指引,德康医疗盘后大涨近6%
异动解读|德康医疗盘后上涨6.28%,Q2业绩全面超预期并上调全年指引
行情直击 · 07-31
异动解读|德康医疗盘后上涨6.28%,Q2业绩全面超预期并上调全年指引
德康医疗获选为首家参与FDA数字健康设备试点项目的企业
格隆汇 · 07-23
德康医疗获选为首家参与FDA数字健康设备试点项目的企业
异动解读|德康医疗盘中下跌5.06%,报70.97美元
行情直击 · 07-23
异动解读|德康医疗盘中下跌5.06%,报70.97美元
异动解读|德康医疗盘中上涨5.6%,机构上调目标价叠加G7获加拿大批准
行情直击 · 07-16
异动解读|德康医疗盘中上涨5.6%,机构上调目标价叠加G7获加拿大批准
德康医疗G7 15天连续血糖监测系统获加拿大卫生部批准:为加拿大成年糖尿病患者延长佩戴时间与监测连续性
美股速递 · 07-14
德康医疗G7 15天连续血糖监测系统获加拿大卫生部批准:为加拿大成年糖尿病患者延长佩戴时间与监测连续性
德康医疗定于2026年7月30日美东时间下午4:30发布2026年第二季度财报并举行电话会议
美股速递 · 07-09
德康医疗定于2026年7月30日美东时间下午4:30发布2026年第二季度财报并举行电话会议
异动解读|德康医疗盘中下跌5.04%,报68.815美元
行情直击 · 06-23
异动解读|德康医疗盘中下跌5.04%,报68.815美元
异动解读|德康医疗盘中上涨5.27%,Connect研究数据彰显G7联合用药显著降糖优势
行情直击 · 06-08
异动解读|德康医疗盘中上涨5.27%,Connect研究数据彰显G7联合用药显著降糖优势
德康医疗:使用GLP-1药物的参与者中,德康G7实现1.4%的糖化血红蛋白降低,对照组仅为0.2%
美股速递 · 06-07
德康医疗:使用GLP-1药物的参与者中,德康G7实现1.4%的糖化血红蛋白降低,对照组仅为0.2%
德康医疗Connect研究显示:G7与多种药物联合使用可显著降低糖化血红蛋白
美股速递 · 06-07
德康医疗Connect研究显示:G7与多种药物联合使用可显著降低糖化血红蛋白
加载更多
公司概况
公司名称:
德康医疗
所属市场:
NASDAQ
上市日期:
--
主营业务:
德康医疗公司是一家于1999年5月在特拉华州注册成立的公司。该公司是一家医疗器械公司,主要专注于设计、开发和商业化连续血糖监测(CGM)系统,用于管理世界各地的患者、护理人员和临床医生的糖尿病。
发行价格:
--
{"stockData":{"symbol":"DXCM","market":"US","secType":"STK","nameCN":"德康医疗","latestPrice":90.8,"timestamp":1786564800000,"preClose":89.53,"halted":0,"volume":5402528,"hourTrading":{"tag":"盘后","latestPrice":90.63,"preClose":90.8,"latestTime":"19:34 EDT","volume":212193,"amount":19266981.18,"timestamp":1786577645691,"change":-0.17,"changeRate":-0.001872,"amplitude":0.001872},"delay":0,"changeRate":0.014185189322014922,"floatShares":376000000,"shares":377360765,"eps":2.536352,"marketStatus":"已收盘","change":1.27,"latestTime":"08-12 16:00:00 EDT","open":89.04,"high":91.04,"low":88.265,"amount":485996864.469568,"amplitude":0.030995,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.536352,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786608000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1113451200000,"exchange":"NASDAQ","adjPreClose":89.53,"preHourTrading":{"tag":"盘前","latestPrice":89,"preClose":89.53,"latestTime":"09:28 EDT","volume":12670,"amount":1133889.79088,"timestamp":1786541280011,"change":-0.53,"changeRate":-0.00592,"amplitude":0.007595},"postHourTrading":{"tag":"盘后","latestPrice":90.63,"preClose":90.8,"latestTime":"19:34 EDT","volume":212193,"amount":19266981.18,"timestamp":1786577645691,"change":-0.17,"changeRate":-0.001872,"amplitude":0.001872},"volumeRatio":0.954081,"impliedVol":0.3889,"impliedVolPercentile":0.1673},"requestUrl":"/m/hq/s/DXCM","defaultTab":"news","newsList":[{"id":"1178443325","title":"异动解读|德康医疗盘中下跌5.01%,报82.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1178443325","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178443325?lang=zh_cn&edition=full","pubTime":"2026-08-05 23:59","pubTimestamp":1785945548,"startTime":"0","endTime":"0","summary":"8月5日,德康医疗盘中下跌5.01%,报82.58美元/股,成交额1.96亿美元。德康医疗所在的医疗保健设备行业中,个股普遍承压,其中直觉外科公司涨0.79%,银休特跌20.79%,波士顿科学跌3.03%,史赛克跌1.29%,雅培跌1.01%。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656352765","title":"Canaccord Genuity上调德康医疗目标价至90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656352765","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656352765?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:26","pubTimestamp":1785831999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4551","LU1923622614.USD","DXCM","LU2125909247.SGD","BK4082","LU1323610961.USD","LU2210149790.SGD","BK4548","IE00BMPRXR70.SGD","LU0266013472.USD","UUP","LU2210150020.SGD","UDN","BK4585","IE00BMPRXN33.USD","GB00BDT5M118.USD","BK4504","LU2125909593.SGD","LU2211815571.USD","LU0354030511.USD","LU2433249047.HKD","LU0354030438.USD","EKG","HEAL","BK4588","BK4534","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656344493","title":"小摩上调德康医疗目标价至82美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656344493","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656344493?lang=zh_cn&edition=full","pubTime":"2026-08-03 10:32","pubTimestamp":1785724325,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2211815571.USD","EKG","LU2095319765.USD","IE00BMPRXR70.SGD","LU0354030511.USD","UDN","BK4588","HEAL","BK4548","BK4082","DXCM","LU2210150020.SGD","LU2125909247.SGD","LU0266013472.USD","LU2433249047.HKD","BK4534","GB00BDT5M118.USD","LU2125909593.SGD","UUP","LU1923622614.USD","IE00BMPRXN33.USD","BK4585","LU1323610961.USD","BK4504","LU2210149790.SGD","BK4551","LU0354030438.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115554443","title":"异动解读|德康医疗盘中上涨7.4%,Q2业绩全面超预期并上调全年营收指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1115554443","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115554443?lang=zh_cn&edition=full","pubTime":"2026-07-31 21:42","pubTimestamp":1785505335,"startTime":"0","endTime":"0","summary":"7月31日,德康医疗盘中上涨7.4%,报81.86美元/股,成交额1.24亿美元。消息面上,公司发布第二季度财报,业绩全面超出市场预期并上调全年营收指引,成为股价上涨的核心催化剂。具体数据方面,Q2调整后每股收益0.70美元,大幅超越分析师一致预期的0.61美元,同比增长45.83%;营收13.08亿美元,超预期的12.90亿美元,同比增长约13%,主要得益于连续血糖监测仪的强劲需求。公司同时将全年营收指引上调至51.8亿至52.5亿美元,此前区间下限为51.6亿美元,进一步增强市场信心。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142009053","title":"异动解读|德康医疗盘前上涨6.65%,Q2业绩全面超预期并上调全年营收指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1142009053","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142009053?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:28","pubTimestamp":1785486517,"startTime":"0","endTime":"0","summary":"7月31日,德康医疗盘前上涨6.65%,报79.3美元/股。消息面上,公司盘后公布第二季度财报,业绩全面超出市场预期并上调全年营收指引,成为股价上涨的核心催化剂。具体数据方面,Q2调整后每股收益0.70美元,大幅超越分析师一致预期的0.61美元,同比增长45.83%;营收13.08亿美元,超预期的12.90亿美元,同比增长约13%。公司同时将全年营收指引上调至51.8亿至52.5亿美元,此前区间下限为51.6亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191666434","title":"异动解读 | 德康医疗夜盘大涨8.18%,Q2业绩全面超预期并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1191666434","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191666434?lang=zh_cn&edition=full","pubTime":"2026-07-31 15:04","pubTimestamp":1785481466,"startTime":"0","endTime":"0","summary":"德康医疗今日夜盘股价大涨8.18%,引发市场广泛关注。消息面上,公司盘后公布的季度财报表现亮眼,成为推动股价上涨的核心催化剂。得益于连续血糖监测仪的强劲需求,德康医疗第二季度营收达到13.1亿美元,同比增长约13%,高于分析师预期的12.9亿美元;调整后每股收益为0.70美元,大幅超越市场预期的0.61美元。同时,公司上调了全年营收指引,预计全年营收将在51.8亿美元至52.5亿美元之间,此前区间下限为51.6亿美元,进一步增强了市场信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DXCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655105333","title":"德康医疗Q2业绩超预期,上调全年营收指引的下限","url":"https://stock-news.laohu8.com/highlight/detail?id=2655105333","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655105333?lang=zh_cn&edition=full","pubTime":"2026-07-31 10:18","pubTimestamp":1785464282,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4534","BK4504","BK4588","LU0354030511.USD","LU2210150020.SGD","BK4548","HEAL","LU2125909593.SGD","LU2211815571.USD","DXCM","LU2095319765.USD","BK4585","IE00BMPRXN33.USD","LU0354030438.USD","LU2125909247.SGD","LU1923622614.USD","LU2433249047.HKD","EKG","BK4551","GB00BDT5M118.USD","LU2210149790.SGD","BK4082","IE00BMPRXR70.SGD","LU1323610961.USD","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136962178","title":"异动解读 | 德康医疗夜盘大涨7.28%,Q2财报超预期并上调全年营收指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1136962178","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136962178?lang=zh_cn&edition=full","pubTime":"2026-07-31 08:08","pubTimestamp":1785456527,"startTime":"0","endTime":"0","summary":"德康医疗今日夜盘股价大涨7.28%,引发市场广泛关注。消息面上,公司盘后公布的季度业绩全面超出市场预期,并上调了全年营收指引,成为推动股价上涨的主要催化剂。得益于连续血糖监测仪的强劲需求,德康医疗第二季度营收达到13.1亿美元,同比增长13%,高于分析师预期的12.9亿美元;调整后每股收益为70美分,同样优于市场预期的61美分。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DXCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100980673","title":"异动解读|德康医疗夜盘上涨7.28%,Q2业绩全面超预期并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1100980673","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100980673?lang=zh_cn&edition=full","pubTime":"2026-07-31 08:04","pubTimestamp":1785456276,"startTime":"0","endTime":"0","summary":"7月31日,德康医疗夜盘上涨7.28%,报79.97美元/股。消息面上,公司盘后公布第二季度财报,业绩全面超出市场预期,并上调全年营收指引,成为股价上涨的核心催化剂。具体数据方面,Q2调整后每股收益0.70美元,大幅超越分析师一致预期的0.61美元,同比增长45.83%;营收13.08亿美元,超预期的12.90亿美元,同比增长约13%。公司同时将全年营收指引上调至51.8亿至52.5亿美元,此前区间下限为51.6亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德康医疗夜盘上涨7.28%,Q2业绩全面超预期并上调全年指引","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114316127","title":"异动解读 | 财报超预期并上调全年指引,德康医疗盘后大涨近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114316127","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114316127?lang=zh_cn&edition=full","pubTime":"2026-07-31 04:37","pubTimestamp":1785443841,"startTime":"0","endTime":"0","summary":"德康医疗(Dexcom,DXCM)今日盘后股价大涨5.98%,引发市场关注。消息面上,公司盘后公布的季度业绩超出市场预期,并上调了全年营收指引,成为股价上涨的主要催化剂。得益于连续血糖监测仪的强劲需求,德康医疗第二季度营收达13.1亿美元,同比增长13%,高于分析师预期的12.9亿美元;调整后每股收益为70美分,同样优于市场预期的61美分。公司还预计全年营收将在51.8亿美元至52.5亿美元之间,较此前指引有所上调,分析师平均预期为52.2亿美元。随着糖尿病护理意识提升以及消费者对无创监测技术的偏好增加,连续血糖监测仪市场需求持续旺盛,推动德康医疗等龙头厂商的业绩表现与市场信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DXCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104022685","title":"异动解读|德康医疗盘后上涨6.28%,Q2业绩全面超预期并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1104022685","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104022685?lang=zh_cn&edition=full","pubTime":"2026-07-31 04:36","pubTimestamp":1785443798,"startTime":"0","endTime":"0","summary":"7月31日,德康医疗盘后上涨6.28%,报78.07美元/股,成交额2080.01万美元。消息面上,公司发布第二季度财报,业绩全面超出市场预期。Q2调整后每股收益0.70美元,大幅超越分析师一致预期的0.61美元,同比增长45.83%;营收13.08亿美元,超预期的12.90亿美元,同比增长约12.9%。同时公司上调全年营收指引至51.8亿至52.5亿美元,此前区间下限为51.6亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653515716","title":"德康医疗获选为首家参与FDA数字健康设备试点项目的企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2653515716","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653515716?lang=zh_cn&edition=full","pubTime":"2026-07-23 13:18","pubTimestamp":1784783902,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4534","GB00BDT5M118.USD","DXCM","LABU","LU2210149790.SGD","LU2210150020.SGD","LU0354030511.USD","IE00BMPRXN33.USD","LU1923622614.USD","HEAL","BK4551","LU2433249047.HKD","LU2211815571.USD","EKG","LU2095319765.USD","BK4588","BK4548","LU0266013472.USD","BK4082","BK4585","LU1323610961.USD","IE00BMPRXR70.SGD","LU0354030438.USD","LU2125909247.SGD","LU2125909593.SGD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137865548","title":"异动解读|德康医疗盘中下跌5.06%,报70.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137865548","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137865548?lang=zh_cn&edition=full","pubTime":"2026-07-23 03:35","pubTimestamp":1784748922,"startTime":"0","endTime":"0","summary":"7月22日,德康医疗盘中下跌5.06%,报70.97美元/股,成交额1.45亿美元。德康医疗所在的医疗保健设备行业中,板块整体表现偏弱,个股中,直觉外科公司跌2.39%,雅培涨0.55%,史赛克跌1.32%,波士顿科学跌0.86%,爱德华兹跌0.48%。德康医疗是一家医疗器械公司,主要专注于设计、开发和商业化连续血糖监测(CGM)系统,用于管理全球患者、护理人员和临床医生的糖尿病,公司定于7月30日发布第二季度财报。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160024485","title":"异动解读|德康医疗盘中上涨5.6%,机构上调目标价叠加G7获加拿大批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1160024485","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160024485?lang=zh_cn&edition=full","pubTime":"2026-07-16 21:59","pubTimestamp":1784210369,"startTime":"0","endTime":"0","summary":"7月16日,德康医疗盘中上涨5.6%,报77.52美元/股,成交额5445.62万美元。消息面上,Truist当日将德康医疗目标价从80美元上调至87美元,维持买入评级。此外,公司G7 15天连续血糖监测系统于7月14日获得加拿大卫生部授权批准,适用于18岁及以上成年糖尿病患者,为加拿大获批的最长续航CGM设备,佩戴时间可达15.5天。公司定于7月30日发布二季度财报,市场预期EPS为0.61美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德康医疗盘中上涨5.6%,机构上调目标价叠加G7获加拿大批准","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192506493","title":"德康医疗G7 15天连续血糖监测系统获加拿大卫生部批准:为加拿大成年糖尿病患者延长佩戴时间与监测连续性","url":"https://stock-news.laohu8.com/highlight/detail?id=1192506493","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192506493?lang=zh_cn&edition=full","pubTime":"2026-07-14 04:46","pubTimestamp":1783975576,"startTime":"0","endTime":"0","summary":"德康医疗G7 15天连续血糖监测系统已获得加拿大卫生部的授权批准。这一进展将为生活在加拿大的成年糖尿病患者带来更长的传感器佩戴时间与更持续的血糖监测体验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0354030438.USD","LU2433249047.HKD","DXCM","LU2125909593.SGD","IE00BMPRXN33.USD","LU2210149790.SGD","LU2210150020.SGD","LU2211815571.USD","BK4585","LU0266013472.USD","BK4082","BK4548","LU2125909247.SGD","BK4588","HEAL","LU0354030511.USD","BK4504","BK4534","IE00BMPRXR70.SGD","BK4551","EKG","LU2095319765.USD","LU1923622614.USD","LU1323610961.USD","GB00BDT5M118.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111877826","title":"德康医疗定于2026年7月30日美东时间下午4:30发布2026年第二季度财报并举行电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1111877826","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111877826?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:31","pubTimestamp":1783600310,"startTime":"0","endTime":"0","summary":"德康医疗已正式确定,将于2026年7月30日美东时间下午4时30分,发布其2026年第二季度的财务业绩报告。届时,公司管理层还将举行一场财报电话会议,与投资者及分析师深入探讨季度表现与业务进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU2433249047.HKD","LU2125909247.SGD","DXCM","BK4551","LU1923622614.USD","LU0266013472.USD","IE00BMPRXR70.SGD","LU2125909593.SGD","LU2211815571.USD","BK4082","BK4585","BK4588","GB00BDT5M118.USD","LU2210149790.SGD","LU1323610961.USD","BK4548","LU0354030438.USD","EKG","LU2210150020.SGD","LU2095319765.USD","IE00BMPRXN33.USD","BK4504","LU0354030511.USD","HEAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151106100","title":"异动解读|德康医疗盘中下跌5.04%,报68.815美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1151106100","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151106100?lang=zh_cn&edition=full","pubTime":"2026-06-23 02:53","pubTimestamp":1782154397,"startTime":"0","endTime":"0","summary":"6月23日,德康医疗盘中下跌5.04%,报68.815美元/股,成交额1.62亿美元。德康医疗所在的医疗保健设备行业中,个股普遍承压,波士顿科学跌2.27%,直觉外科公司跌1.23%,史赛克跌0.93%,雅培跌0.23%,美敦力跌0.1%。德康医疗是一家医疗器械公司,主要专注于设计、开发和商业化连续血糖监测(CGM)系统,用于管理全球患者、护理人员和临床医生的糖尿病。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193007755","title":"异动解读|德康医疗盘中上涨5.27%,Connect研究数据彰显G7联合用药显著降糖优势","url":"https://stock-news.laohu8.com/highlight/detail?id=1193007755","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193007755?lang=zh_cn&edition=full","pubTime":"2026-06-08 22:06","pubTimestamp":1780927593,"startTime":"0","endTime":"0","summary":"6月8日,德康医疗盘中上涨5.27%,报76.83美元/股,成交额7314.0万美元。消息面上,德康医疗公布Connect研究最新数据,该里程碑式临床研究证实,G7持续血糖监测系统与GLP-1受体激动剂联合使用,可实现糖化血红蛋白平均降低1.4%,远超对照组0.2%的改善幅度。此外,G7与二甲双胍、SGLT2抑制剂等多种药物联用均展现出显著临床获益,为非胰岛素治疗的2型糖尿病患者提供了迄今最有力的CGM循证依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182968297","title":"德康医疗:使用GLP-1药物的参与者中,德康G7实现1.4%的糖化血红蛋白降低,对照组仅为0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182968297","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182968297?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:45","pubTimestamp":1780771518,"startTime":"0","endTime":"0","summary":"在最新研究中,德康医疗的G7连续血糖监测系统展现出了显著优势。对于正在使用GLP-1受体激动剂类药物的参与者而言,配合使用德康G7设备,其糖化血红蛋白水平平均降低了1.4%。这一降幅远超对照组仅0.2%的改善,凸显了联合监测方案在血糖管理中的增效作用。研究数据进一步证实,将先进的实时血糖监测技术与新型降糖药物相结合,能为患者带来更为精准和有效的糖尿病控制效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","LU1923622614.USD","BK4585","DXCM","BK4588","BK4534","LU1323610961.USD","BK4548","LU2210150020.SGD","LU0354030438.USD","IE00BMPRXR70.SGD","LU2210149790.SGD","LU2125909247.SGD","BK4504","IE00BMPRXN33.USD","LU2125909593.SGD","LU2433249047.HKD","LU2211815571.USD","LU2095319765.USD","LU0266013472.USD","BK4082","LU0354030511.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139993429","title":"德康医疗Connect研究显示:G7与多种药物联合使用可显著降低糖化血红蛋白","url":"https://stock-news.laohu8.com/highlight/detail?id=1139993429","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139993429?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:45","pubTimestamp":1780771518,"startTime":"0","endTime":"0","summary":"德康医疗的Connect研究数据表明,当将其G7持续血糖监测系统与包括二甲双胍、GLP-1受体激动剂及SGLT2抑制剂在内的多种药物组合方案联用时,能够实现具有临床意义的糖化血红蛋白降低。\n这项发现突显了整合先进监测技术与多元化药物治疗在糖尿病管理中的协同潜力,为优化患者血糖控制提供了新的循证依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211815571.USD","BK4551","LU0266013472.USD","BK4504","BK4082","BK4585","BK4534","LU2125909247.SGD","BK4588","LU1923622614.USD","LU0354030511.USD","DXCM","IE00BMPRXR70.SGD","LU2210149790.SGD","LU2433249047.HKD","BK4548","LU0354030438.USD","LU2095319765.USD","IE00BMPRXN33.USD","LU2125909593.SGD","LU2210150020.SGD","LU1323610961.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dexcom.com;investors.dexcom.com","stockEarnings":[{"period":"1week","weight":0.0298},{"period":"1month","weight":0.1944},{"period":"3month","weight":0.5286},{"period":"6month","weight":0.3757},{"period":"1year","weight":0.15},{"period":"ytd","weight":0.349}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0207},{"period":"3month","weight":0.0381},{"period":"6month","weight":0.1311},{"period":"1year","weight":0.2117},{"period":"ytd","weight":0.13}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"德康医疗公司是一家于1999年5月在特拉华州注册成立的公司。该公司是一家医疗器械公司,主要专注于设计、开发和商业化连续血糖监测(CGM)系统,用于管理世界各地的患者、护理人员和临床医生的糖尿病。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.06713},{"month":2,"riseRate":0.428571,"avgChangeRate":0.005394},{"month":3,"riseRate":0.571429,"avgChangeRate":0.008909},{"month":4,"riseRate":0.571429,"avgChangeRate":0.053795},{"month":5,"riseRate":0.590909,"avgChangeRate":0.039223},{"month":6,"riseRate":0.727273,"avgChangeRate":0.051799},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.003842},{"month":8,"riseRate":0.772727,"avgChangeRate":0.082794},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.041914},{"month":10,"riseRate":0.380952,"avgChangeRate":-0.03167},{"month":11,"riseRate":0.571429,"avgChangeRate":0.032818},{"month":12,"riseRate":0.571429,"avgChangeRate":0.046062}],"exchange":"NASDAQ","name":"德康医疗","nameEN":"DexCom"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"德康医疗(DXCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供德康医疗(DXCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"德康医疗,DXCM,德康医疗股票,德康医疗股票老虎,德康医疗股票老虎国际,德康医疗行情,德康医疗股票行情,德康医疗股价,德康医疗股市,德康医疗股票价格,德康医疗股票交易,德康医疗股票购买,德康医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"德康医疗(DXCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供德康医疗(DXCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}